000			03319cam a2200349 a 4500
003			EG-GiCUC
005			20250223031735.0
008			170617s2016 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.19.M.Sc.2016.No.A
100	0		_aNoha Refaat Mahmoud
245	1	0	_aAntimicrobial activity of Cefepime-Tazobactam combination against extended Spectrum Beta- Lactamase and/or AampC Beta-Lactamase- producing gram-negative bacilli / _cNoha Refaat Mahmoud ; Supervised Azza Essam Eldin Badr , Hala Elsayed Badawi , Basma Ahmed Elawady
246	1	5	_aتأثير مركب السيفيبيم- تازوباكتم ضد العصويات سالبة التصبغ المنتجة لإنزيمات البيتا لاكتميز ممتدة المفعول أوالأم-بي-سي
260			_aCairo : _bNoha Refaat Mahmoud , _c2016
300			_a113 P. : _bcharts , facsimils ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Microbiology and Immunology
520			_aIntroduction: The purpose of this study was to evaluate the sensitivity of cefepime /tazobactam combination against ESBL- and/or AmpC-producing Gram-negative bacilli. Materials and method: The study was conducted on 100 Gram-negative bacilli. ESBL production was screened by using the disc diffusion test and was confirmed by the combined disc confirmatory test, screening of AmpC production was done by cefoxitin disc test and confirmation was done by AmpC disc test. Isolates confirmed positive for ESBL and/ or AmpC production were investigated for their susceptibility to the following antibiotics: cefepime, imipenem, ertapenem, meropenem, piperacillin/tazobactam, cefoperazone/sulbactam and cefepime/tazobactam. Results: Among 100 Gram-negative bacilli, 56 isolates screened positive for ESBL production by the disc diffusion test and 44 were confirmed as ESBL producers by the combined disc confirmatory test. Thirty-two isolates were screened positive for AmpC production by cefoxitin disc test and 9 isolates were confirmed as AmpC producers by AmpC disc test. Using MAST D68C set, 32 isolates were ESBL producers, 3 were AmpC producers, and 4 isolates were both ESBL and AmpC producers. Forty-three isolates were sensitive to cefepime/tazobactam combination, 10 isolates were sensitive to cefoperazone/sulbactam, 13 isolates were sensitive to piperacillin/tazobactam, 37 isolates were sensitive to meropenem, 32 isolates were sensitive to ertapenem, 37 isolates were sensitive to imipenem and 8 isolates were sensitive to cefepime. Conclusion: Cefepime/tazobactam revealed excellent activity against ESBL and/or AmpC-producing Gram-negative bacilli and may be considered as a therapeutic alternative to carbapenems in infections caused by these organisms
530			_aIssued also as CD
653		4	_aAntimicrobial Activity
653		4	_aCefepime-tazobactam combination
653		4	_aSpectrum beta- Lactamase
700	0		_aAzza Essam Eldin Badr , _eSupervisor
700	0		_aBasma Ahmed Elawady , _eSupervisor
700	0		_aHala Elsayed Badawi , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c61284 _d61284